Pfizer touts monthly injectable PF‑3944 as practical obesity challenger amid Trump drug pricing push
- Pfizer's long-acting PF′3944 showed up to 12.3% greater weight loss versus placebo at week 28.
- Pfizer bought Metsera for roughly $10 billion, signaling a renewed push into the obesity market.
- Pfizer plans ten phase‑3 trials aiming for 2028 approvals, including switch trials from weekly GLP‑1 therapies.
Pfizer targets monthly injectable as a practical challenger in obesity market
Pfizer is positioning its long-acting injectable PF′3944 as a potential game-changer in obesity treatment after releasing mid-stage data showing up to 12.3% greater weight loss versus placebo at week 28. The company is presenting results in June and says the regimen, which starts with 12 weeks of weekly injections before switching to monthly dosing, shows no plateau after the switch and continues to drive weight loss through the planned 64-week study period. Pfizer is highlighting tolerability and convenience as differentiators against weekly GLP‑1 injectables and new oral entrants.
The drug follows Pfizer’s roughly $10 billion Metsera acquisition and signals the company’s renewed push into the obesity space, where market leadership is held by Eli Lilly and Novo Nordisk. CEO Albert Bourla characterises the candidate as having a “very competitive profile in tolerability and efficacy,” and company modelling suggests a higher phase‑3 dose could produce roughly 16% weight loss at week 28. Pfizer plans to launch ten phase‑3 trials aimed at potential approvals in 2028, including studies that allow patients on existing weekly GLP‑1 therapies to switch to PF′3944 as a maintenance option.
Company executives stress trial design priorities that include diverse patient enrolment, higher dose testing, longer safety follow‑up and switch trials from current therapies. They say regulatory timelines and commercial positioning will hinge on the full June readout and subsequent phase‑3 outcomes. The emphasis on monthly dosing and a robust tolerability profile aims to address adherence and convenience, two commercial levers Pfizer intends to use to capture share in a rapidly evolving obesity treatment market.
White House roll-out draws industry attention
Separately, the Trump administration launches TrumpRx.gov, a government‑backed website meant to give consumers access to discounted drugs under most‑favoured‑nation style pricing deals. President Donald Trump says 16 of the 17 largest drugmakers have agreed to extend low Medicaid prices to cash‑paying consumers; media coverage of the launch references Pfizer among the companies being watched by policymakers.
Related Cashu News

Bristol-Myers Squibb's Reclassification Enhances Growth Potential in Defensive Investment Strategy
Bristol-Myers Squibb Company (Ticker: BMY) undergoes a key reclassification across the Russell indexes, marking a transformative moment for the company. Moving to the Russell 1000 Defensive and Russel…

Vertex Pharmaceuticals' Casgevy Gains FDA Approval for Expanded Sickle Cell Disease Treatment Options
Vertex Pharmaceuticals (Ticker: VRTX) receives a significant boost in its ongoing battle against sickle cell disease with the recent FDA approval of an expanded label for its gene therapy product, Cas…

Gilead Sciences Gains FDA Approval for Trodelvy in First-Line Triple-Negative Breast Cancer Treatment
Gilead Sciences (Ticker: GILD) makes significant strides in oncology therapy with the recent approval of its drug Trodelvy for patients with unresectable or metastatic triple-negative breast cancer. T…

Merck Advances HIV Treatment and Faces Regulatory Scrutiny Amidst Market Success
Merck & Co. (Ticker: MRK) has recently made significant strides in the pharmaceutical landscape, particularly with its advancements in HIV treatment. The company's innovative drug, IDVYNSO, has receiv…

